Rattanasupar Attapon, Sengmanee Siriwan
J Med Assoc Thai. 2016 Sep;99(9):988-95.
Gastrointestinal bleeding with non-portal hypertension bleeding (non-PHT) is the most common cause of gastrointestinal emergencies with high mortality rate. The majority of non-PHT patient stem from acid related disease. The practice guideline recommends using pre-endoscopic proton pump inhibitors (PPIs). However, the dose and route of PPIs administration were still unclear according to the Association for Gastroenterology.
To compare the efficiency of PPIs between high dose and standard dose before endoscopy in patients suffering with gastrointestinal bleeding due to non-PHT.
The present study was designed as a prospective, randomized controlled trial. The patients were randomly categorized into two groups, the first group received intravenous pantoprazole 80 mg bolus then continuously drip 8 mg per hour (high dose group) and the other group received intravenous pantoprazole 40 mg twice daily before endoscopy (standard dose group). Baseline characteristics, Blatchford score, endoscopic findings, morbidity, and other complications were recorded.
One hundred thirteen patients were recruited. Fifty-eight patients were in the high dose group and 55 patients in the standard dose group. Blatchford scores in the high dose group were slightly higher than the standard dose group but there was no statistically significant difference (12.49+3.29 and 12.38+4.06, respectively, p = 0.876). Twenty-two patients were high-risk for peptic ulcer bleeding from endoscopy. There were significantly less numbers of patient who were high-risk of peptic ulcer bleeding in the high dose group compared to the standard dose group (10 patients [17.24%] and 12 patients [21.82%], respectively, p = 0.025). There was no difference between the two groups in average time of hospital stay (3.03 and 2.89 days, respectively, p>0.05), mean unit of blood transfusion (1.79 and 1.63 units, respectively, p>0.05), and the complications after endoscopy such as recurrent bleeding (0 and 1 patient, respectively, p>0.05), recurrent bleeding and death (0 and 1 patient, respectively, p>0.05). The Blatchford score greater than 10, 11, and 12 showed high sensitivity of 100%, 95%, and 95% respectively with negative predictive values (NPV) of 100%, 97%, and 97% respectively, in predicting high-risk peptic ulcer bleeding.
The high dose of PPIs administration before endoscopy reduced the chance of high-risk peptic ulcer bleeding compared to the standard dose. Both high dose and standard dose of PPIs did not affect the time of hospital stay, unit of blood transfusion, the complications after endoscopy, and mortality rate. Standard dose PPIs can be considered using in patients with Blatchford scores lower than 10. High dose PPIs would be beneficial in patients who have Blatchford scores between 10 and 12. For patients who have Blatchford scores greater than 12, high dose PPIs are recommended.
非门静脉高压性出血(non-PHT)所致的胃肠道出血是胃肠道急症最常见的病因,死亡率高。大多数非PHT患者源于酸相关性疾病。实践指南推荐在内镜检查前使用质子泵抑制剂(PPI)。然而,根据胃肠病学协会的观点,PPI的给药剂量和途径仍不明确。
比较非PHT所致胃肠道出血患者内镜检查前高剂量和标准剂量PPI的疗效。
本研究设计为一项前瞻性随机对照试验。患者被随机分为两组,第一组静脉推注泮托拉唑80mg,然后以每小时8mg持续滴注(高剂量组),另一组在内镜检查前每日两次静脉注射泮托拉唑4mg(标准剂量组)。记录基线特征、布莱奇福德评分、内镜检查结果、发病率及其他并发症。
共纳入113例患者。高剂量组58例,标准剂量组55例。高剂量组的布莱奇福德评分略高于标准剂量组,但差异无统计学意义(分别为12.49±3.29和12.38±4.06,p = 0.876)。22例患者经内镜检查有消化性溃疡出血高风险。与标准剂量组相比,高剂量组消化性溃疡出血高风险患者数量显著更少(分别为10例[17.24%]和12例[21.82%],p = 0.025)。两组的平均住院时间(分别为3.03天和2.89天,p>0.05)、平均输血量(分别为1.79单位和1.63单位,p>0.05)以及内镜检查后的并发症如再出血(分别为0例和1例,p>0.05)、再出血和死亡(分别为0例和1例,p>0.05)无差异。布莱奇福德评分大于10、11和12时,预测消化性溃疡出血高风险的敏感度分别为100%、95%和95%;阴性预测值(NPV)分别为100%、97%和97%。
与标准剂量相比,内镜检查前高剂量使用PPI可降低消化性溃疡出血高风险的几率。高剂量和标准剂量的PPI均不影响住院时间、输血量、内镜检查后的并发症及死亡率。布莱奇福德评分低于10的患者可考虑使用标准剂量PPI。布莱奇福德评分在10至12之间的患者,高剂量PPI有益。对于布莱奇福德评分大于12的患者,推荐使用高剂量PPI。